Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Kappa opioid regulation of depressive-like behavior during acute withdrawal and protracted abstinence from ethanol.

Jarman SK, Haney AM, Valdez GR.

PLoS One. 2018 Sep 28;13(9):e0205016. doi: 10.1371/journal.pone.0205016. eCollection 2018.

2.

nor-BNI Antagonism of Kappa Opioid Agonist-Induced Reinstatement of Ethanol-Seeking Behavior.

Harshberger E, Gilson EA, Gillett K, Stone JH, El Amrani L, Valdez GR.

J Addict. 2016;2016:1084235. Epub 2016 Nov 6.

3.

Protracted withdrawal from ethanol and enhanced responsiveness stress: regulation via the dynorphin/kappa opioid receptor system.

Gillett K, Harshberger E, Valdez GR.

Alcohol. 2013 Aug;47(5):359-65. doi: 10.1016/j.alcohol.2013.05.001. Epub 2013 May 31.

4.

κ opioid regulation of anxiety-like behavior during acute ethanol withdrawal.

Valdez GR, Harshberger E.

Pharmacol Biochem Behav. 2012 Jul;102(1):44-7. doi: 10.1016/j.pbb.2012.03.019. Epub 2012 Apr 2.

5.

Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence.

Walker BM, Valdez GR, McLaughlin JP, Bakalkin G.

Alcohol. 2012 Jun;46(4):359-70. doi: 10.1016/j.alcohol.2011.10.006. Epub 2012 Mar 27. Review.

6.
7.

Intravenous self-administration of etonitazene alone and combined with cocaine in rhesus monkeys: comparison with heroin and antagonism by naltrexone and naloxonazine.

Achat-Mendes C, Valdez GR, Platt DM, Rowlett JK, Spealman RD.

Psychopharmacology (Berl). 2009 Jun;204(3):489-98. doi: 10.1007/s00213-009-1480-0. Epub 2009 Feb 19.

8.

Subtype-selective corticotropin-releasing factor receptor agonists exert contrasting, but not opposite, effects on anxiety-related behavior in rats.

Zhao Y, Valdez GR, Fekete EM, Rivier JE, Vale WW, Rice KC, Weiss F, Zorrilla EP.

J Pharmacol Exp Ther. 2007 Dec;323(3):846-54. Epub 2007 Sep 12.

PMID:
17855476
9.

Kappa agonist-induced reinstatement of cocaine seeking in squirrel monkeys: a role for opioid and stress-related mechanisms.

Valdez GR, Platt DM, Rowlett JK, Rüedi-Bettschen D, Spealman RD.

J Pharmacol Exp Ther. 2007 Nov;323(2):525-33. Epub 2007 Aug 16.

PMID:
17702903
10.
11.

Stress enhancement of craving during sobriety: a risk for relapse.

Breese GR, Chu K, Dayas CV, Funk D, Knapp DJ, Koob GF, Lê DA, O'Dell LE, Overstreet DH, Roberts AJ, Sinha R, Valdez GR, Weiss F.

Alcohol Clin Exp Res. 2005 Feb;29(2):185-95.

12.

Measuring meals: structure of prandial food and water intake of rats.

Zorrilla EP, Inoue K, Fekete EM, Tabarin A, Valdez GR, Koob GF.

Am J Physiol Regul Integr Comp Physiol. 2005 Jun;288(6):R1450-67. Epub 2005 Jan 6.

13.

Leptin and post-prandial satiety: acute central leptin more potently reduces meal frequency than meal size in the rat.

Zorrilla EP, Inoue K, Valdez GR, Tabarin A, Koob GF.

Psychopharmacology (Berl). 2005 Jan;177(3):324-35. Epub 2004 Jul 27.

PMID:
15609069
14.
15.
16.

Reduction of anxiety after restricted feeding in the rat: implication for eating disorders.

Inoue K, Zorrilla EP, Tabarin A, Valdez GR, Iwasaki S, Kiriike N, Koob GF.

Biol Psychiatry. 2004 Jun 1;55(11):1075-81.

PMID:
15158426
17.

Human urocortin 2, a corticotropin-releasing factor (CRF)2 agonist, and ovine CRF, a CRF1 agonist, differentially alter feeding and motor activity.

Zorrilla EP, Reinhardt LE, Valdez GR, Inoue K, Rivier JE, Vale WW, Koob GF.

J Pharmacol Exp Ther. 2004 Sep;310(3):1027-34. Epub 2004 Apr 28.

PMID:
15115804
18.

Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist.

Valdez GR, Zorrilla EP, Rivier J, Vale WW, Koob GF.

Brain Res. 2003 Aug 8;980(2):206-12.

PMID:
12867260
19.
20.

Human urocortin II, a selective agonist for the type 2 corticotropin-releasing factor receptor, decreases feeding and drinking in the rat.

Inoue K, Valdez GR, Reyes TM, Reinhardt LE, Tabarin A, Rivier J, Vale WW, Sawchenko PE, Koob GF, Zorrilla EP.

J Pharmacol Exp Ther. 2003 Apr;305(1):385-93.

PMID:
12649393
21.

Increased ethanol self-administration and anxiety-like behavior during acute ethanol withdrawal and protracted abstinence: regulation by corticotropin-releasing factor.

Valdez GR, Roberts AJ, Chan K, Davis H, Brennan M, Zorrilla EP, Koob GF.

Alcohol Clin Exp Res. 2002 Oct;26(10):1494-501.

PMID:
12394282
22.

Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat.

Zorrilla EP, Valdez GR, Nozulak J, Koob GF, Markou A.

Brain Res. 2002 Oct 18;952(2):188-99.

PMID:
12376179
23.

Human urocortin II: mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide.

Valdez GR, Inoue K, Koob GF, Rivier J, Vale W, Zorrilla EP.

Brain Res. 2002 Jul 5;943(1):142-50.

PMID:
12088848
24.

Changes in levels of regional CRF-like-immunoreactivity and plasma corticosterone during protracted drug withdrawal in dependent rats.

Zorrilla EP, Valdez GR, Weiss F.

Psychopharmacology (Berl). 2001 Dec;158(4):374-81. Epub 2001 Jun 13.

PMID:
11797058
25.

Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors.

Weiss F, Ciccocioppo R, Parsons LH, Katner S, Liu X, Zorrilla EP, Valdez GR, Ben-Shahar O, Angeletti S, Richter RR.

Ann N Y Acad Sci. 2001 Jun;937:1-26. Review.

PMID:
11458532

Supplemental Content

Loading ...
Support Center